Septerna (NASDAQ:SEPN) Sets New 12-Month High – Still a Buy?

Septerna, Inc. (NASDAQ:SEPN) shares hit a new 52-week high during mid-day trading on Monday . The stock traded as high as $29.43 and last traded at $28.4550, with a volume of 326676 shares changing hands. The stock had previously closed at $25.56.

Analyst Upgrades and Downgrades

Several research firms have recently commented on SEPN. Cantor Fitzgerald restated an “overweight” rating and issued a $25.00 target price on shares of Septerna in a research note on Friday, September 5th. Wall Street Zen raised shares of Septerna from a “sell” rating to a “buy” rating in a report on Sunday, November 16th. Wells Fargo & Company upgraded shares of Septerna from an “equal weight” rating to an “overweight” rating and raised their price objective for the company from $18.00 to $28.00 in a research report on Friday, November 14th. HC Wainwright boosted their target price on Septerna from $26.00 to $30.00 and gave the stock a “buy” rating in a research report on Tuesday, November 11th. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Septerna in a research note on Wednesday, October 8th. Three analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus target price of $27.67.

Septerna Stock Performance

The stock’s 50-day moving average price is $20.75 and its 200-day moving average price is $14.73. The company has a market capitalization of $1.32 billion and a price-to-earnings ratio of -19.58.

Septerna (NASDAQ:SEPN) last released its quarterly earnings results on Monday, November 10th. The company reported ($0.09) earnings per share for the quarter, missing analysts’ consensus estimates of $0.19 by ($0.28). Septerna had a negative return on equity of 17.98% and a negative net margin of 266.77%.The firm had revenue of $21.50 million during the quarter, compared to analyst estimates of $24.50 million. Analysts anticipate that Septerna, Inc. will post -7.11 earnings per share for the current year.

Insider Buying and Selling at Septerna

In other news, SVP Daniel D. Long sold 3,501 shares of the firm’s stock in a transaction on Monday, November 10th. The stock was sold at an average price of $18.06, for a total value of $63,228.06. Following the completion of the transaction, the senior vice president owned 92,911 shares in the company, valued at $1,677,972.66. This trade represents a 3.63% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through the SEC website. 4.30% of the stock is currently owned by corporate insiders.

Hedge Funds Weigh In On Septerna

A number of institutional investors have recently made changes to their positions in the stock. KLP Kapitalforvaltning AS purchased a new position in shares of Septerna during the 1st quarter worth $49,000. XTX Topco Ltd acquired a new position in Septerna in the first quarter valued at $216,000. Chicago Partners Investment Group LLC acquired a new position in Septerna in the first quarter valued at $63,000. TRV GP VI LLC lifted its position in Septerna by 33.6% during the first quarter. TRV GP VI LLC now owns 4,211,659 shares of the company’s stock worth $24,386,000 after buying an additional 1,059,203 shares during the period. Finally, Deutsche Bank AG boosted its stake in Septerna by 53.3% in the 1st quarter. Deutsche Bank AG now owns 15,968 shares of the company’s stock worth $92,000 after buying an additional 5,549 shares during the last quarter.

Septerna Company Profile

We are a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) oral small molecule drug discovery powered by our proprietary Native Complex Platform™. Our industrial-scale platform aims to unlock the full potential of GPCR therapies and has led to the discovery and development of our deep pipeline of product candidates focused initially on treating patients in three therapeutic areas: endocrinology, immunology and inflammation, and metabolic diseases.